Ibalizumab, a drug that works against multi-drug-resistant HIV, is now available via the manufacturer's expanded access program.
In a way, the story of ibalizumab is a time travel tale back to 1994, before any protease inhibitor drugs were approved.
For the small percentage of HIV patients struggling with drug resistance, an expanded access program for a new injectable treatment might be the answer.
Drug resistance can happen when HIV changes its shape in a way that stops a drug from working. This slideshow gives the basics of preventing or dealing with drug resistance.
Get basic information about tests for resistance, tropism, and viral load -- what they are, when you need them, and how they are used.
A vulnerable and often forgotten minority of people with HIV struggle with multi-drug resistant HIV (MDR-HIV) while waiting for ARVs that would finally control their viral replication. Fortunately, clinical trials will now provide access to two new d...
Is HIV resistance something you have to worry about? With antiretrovirals being stronger than ever and keeping people living with HIV (PLWHA) living longer than ever, resistance is a topic that worries a lot of people. We know meds are effective -- a...